Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05433584 · ClinicalTrials.gov registry record · Phase 4
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
A Phase 4 study of Type 2 Diabetes, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 4
- Development phase
- 780
- Enrollment target
- 20
- Study locations
NCT05433584: Active Phase 4 study of Type 2 Diabetes, sponsored by Eli Lilly and Company.
NCT05433584 is a Phase 4 study of Type 2 Diabetes that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 780 participants, below the 3,921-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05433584, a Phase 4 study of Type 2 Diabetes, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 780 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.
Conditions Studied
Interventions
- DRUG Tirzepatide
- DRUG Antihyperglycemic medication
Study Locations (20)
California
- San Fernando Valley Health Institute - Canoga Park
- Velocity Clinical Research, Huntington Park - Huntington Park
- Velocity Clinical Research, San Diego - La Mesa
- Clinical Trials Research - Lincoln
- Velocity Clinical Research, Westlake - Los Angeles
- Catalina Research Institute, LLC - Montclair
- Velocity Clinical Research, North Hollywood - North Hollywood
- Velocity Clinical Research, Panorama City - Panorama City
- Western University of Health Sciences - Pomona
- Velocity Clinical Research, Santa Ana - Santa Ana
Florida
- Excel Medical Clinical Trials - Boca Raton
- Alliance for Multispecialty Research, LLC - Coral Gables
- South Florida Clinical Research Institute - Margate
Georgia
- Emory University School of Medicine- Grady Campus - Atlanta
- Center for Advanced Research & Education - Gainesville
Alabama
- Cahaba Research - Trussville - Birmingham
Connecticut
- New England Research Associates, LLC - Bridgeport
Indiana
- Qualmedica Research, LLC - Evansville
Iowa
- Iowa Diabetes and Endocrinology Research Center - West Des Moines
Kentucky
- Qualmedica Research - Bowling Green
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 780 participants |
| Start Date | 2022-08-01 |
| Est. Completion | 2027-11 |
| Phase | Phase 4 |
What the registry record for NCT05433584 still lists
NCT05433584 is an interventional study that assigns participants to a tested intervention. The registered 780 participants enrollment target is mid-sized for trials with a published cap, below the 3,921-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Tirzepatide is the first listed.
NCT05433584 names 20 study sites across 8 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT05433584 about?
NCT05433584 is a clinical study titled "A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes". This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.
What is the current status of trial NCT05433584?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 780 participants. The study started on 2022-08-01. Estimated completion is 2027-11.
What conditions does trial NCT05433584 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT05433584?
The interventions under investigation include: Tirzepatide (DRUG), Antihyperglycemic medication (DRUG).
Who is sponsoring clinical trial NCT05433584?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05433584 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05433584's enrollment target sits among peer trials
780 33rd of 327 higher than 295 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mechanism of SGLT2 Inhibition in the Kidney
RECRUITING · Phase 4
-
GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH
RECRUITING · Phase 4
-
DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes
RECRUITING · Phase 4
-
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
RECRUITING · Phase 4
-
Quantifying Hepatic Mitochondrial Fluxes in Humans
RECRUITING · Phase 4
-
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05046613 · 780 participants
Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
- NCT05100862 · 780 participants · Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
- NCT05513872 · 780 participants · Phase 1
Overcoming Nicotine Dependence to Enable Quitting
- NCT06310031 · 780 participants · NA
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI